510(k) Report

510(k) · Cleared

Cleared

Capture-CMV

K203612510(k) TraditionalCleared Mar 22, 2021102-day reviewClass II21 CFR 866.3175

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Immucor, Inc. · LJO Antigen, Iha, Cytomegalovirus

Cleared on Mar 22, 2021 as substantially equivalent to K183571 (Immucor, Inc., 2019) after a 102-day review. Its family tree reaches back 2 generations to 1991.

Decided
Mar 22, 2021
Review
102 days
Class
Class II
Product code
LJO
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K910003 (1991). No later device cites it as a predicate yet.

K910003 · Cytomegalovirus Antibody Screen · Immucor, Inc. · 1991K183571 · Capture-CMV · Immucor, Inc. · 20191990199520002005201020152020
  1. Root · 2 generations backK910003 Cytomegalovirus Antibody ScreenImmucor, Inc. · 1991
  2. 1 generation backK183571 Capture-CMVImmucor, Inc. · 2019
  3. This deviceK203612 Capture-CMVImmucor, Inc. · 2021
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K910003Cytomegalovirus Antibody ScreenImmucor, Inc.1991—
−1K183571Capture-CMVImmucor, Inc.2019—
0 (this device)K203612Capture-CMVImmucor, Inc.2021—
FIG. 1 — Lineage of K203612, 1991–2021Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LJO? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K183571Capture-CMV
Summary page 4
…Predicate Device Information Trade/Device Name: Capture-CMV® Clearance: K183571 (cleared February 4, 2019) Purpose of the Submission To demonstrate performance of the Capture-CMV® assay on the upg…
Immucor, Inc.2019—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 30 years and passes through 1 company; a new generation was cleared every 27.9 years on median.
  • None of the 2 ancestors has a recall.

How does its category compare?

All LJO devices

LJO Antigen, Iha, Cytomegalovirus: FDA decisions, review times, recalls and adverse event reports over 20 years. 2021, this device’s year, is highlighted.

FDA decisions per year · LJO

1in 2021

2019: 12021: 1
2007high 1 (2019) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LJO

Too few LJO 510(k)s in any year since 2007 to give a median.

Recalls per year · LJO

No recall names LJO since 2007.

Adverse event reports per year · LJO

1in 2018

2011: 22016: 12018: 1
2007high 2 (2011) · low 0 (2007)2025

MAUDE reports naming product code LJO, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—02
20120—00
20130—00
20140—00
20150—00
20160—01
20170—00
20180—01
20191—00
20200—00
20211—00
20220—00
20230—00
20240—00
20250—00
20260—0—

What is it indicated for?

Capture-CMV® is an in vitro qualitative solid phase red cell adherence test system for the detection of antibodies (IgG plus IgM) to cytomegalovirus (CMV) in human serum or plasma. Capture-CMV® is intended to be used in screening of patients for serological evidence of previous infection by CMV using manual and semi-automated methods, NEO Iris® and Galileo NEO®.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K203612: Capture-CMV.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K203612

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026